Printer Friendly

ZILA'S ORASCAN APPLICATION ADVANCES AT FDA

 ZILA'S ORASCAN APPLICATION ADVANCES AT FDA
 PHOENIX, Oct. 26 /PRNewswire/ -- Zila, Inc. (NASDAQ: ZILA),


President Joseph Hines announced today that "Zila has moved significantly closer to gaining approval from U.S. Food and Drug Administration (FDA) to market Orascan in the United States."
 Hines said the FDA informed Zila that the clinical data submitted by the company is sufficient to permit its review as a part of the Orascan final application. "All that remains," said Hines, "is for Zila to supply FDA with details on manufacturing, packaging, stability, labeling, etc. This information will be submitted promptly."
 "The critical issue for Orascan -- as it is for any major new cancer-related product -- is gaining FDA approval of the clinical data in support of the product's safety and efficacy," Hines added. "FDA's finding of 'sufficiency for review' is a major step forward in this direction."
 Zila announced on Oct. 19, 1992, that it plans to begin marketing Orascan in Canada early in 1993. Hines reported that in Canada, "Regulatory issues have been resolved and a letter of intent has been signed with a Canadian firm for production and distribution." Zila is pursuing regulatory approval for Orascan in the U.K. and other markets internationally.
 Hines noted: "Zila is gaining valuable practical experience as we gear up for production, packaging and distribution of Orascan in Canada. This should increase the efficiency of our Orascan roll-out in the U.S."
 No lethal disease is easier to cure than oral cancer detected in its early stages. Yet in 1991, there were 31,000 new cases of oral cancer, 8,150 deaths and $655 million in treatment expenses in the U.S. alone. In the U.S., Orascan would be the first commercially marketed early detection system for oral cancer. It will be used by dentists and physicians to conduct highly accurate oral cancer screens on patients during routine office visits.
 Zila currently markets Zilactin for canker sores, Zilactol for cold sores and fever blisters even before they break out, ZilaDent for cuts and sores caused by dentures and braces, DermaFlex anesthetic gel for minor skin cuts and rashes, and new PeriGel oral care system for healthy teeth and gums.
 -0- 10/26/92
 /NOTE: Orascan, PeriGel and Zilactin are registered trademarks. Zilactol, ZilaDent and DermaFlex are trademarks./
 /CONTACT: Joseph Hines of Zila, Inc., 602-266-6700/
 (ZILA) CO: Zila, Inc.; Food and Drug Administration ST: Arizona IN: MTC SU: PDT


MP-DS -- DC004 -- 4560 10/26/92 08:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 26, 1992
Words:411
Previous Article:APPLE COMPUTER LAUNCHES AGGRESSIVE UNIX VAR RECRUITMENT PROGRAM
Next Article:POWEREX SUBSIDIARY TO SELL SEMICONDUCTORS TO JAPANESE MARKET
Topics:


Related Articles
ZILA, INC., CHOSEN FOR 'THE INC. 100,' AMERICA'S FASTEST-GROWING SMALL PUBLIC COMPANIES
ZILA, INC., POSTS RECORD FOURTH QUARTER SALES; FY 1993 STARTS STRONG
ZILA, INC. POSTS RECORD PROFITS
ZILA SIX MONTH SALES AND EARNINGS BREAK RECORDS
ZILA PHARMACEUTICALS, INC., SETS CANADIAN MANUFACTURING AND SALES AGREEMENT FOR ORASCAN
ZILA PHARMACEUTICALS, INC., APPROVED TO MARKET ORASCAN IN AUSTRALIA
ZILA LICENSES "FORTUNE 500" COMPANY TO MARKET ORASCAN IN EUROPE & AUSTRALIA
ZILA TO OPEN U.S. PRODUCTION FACILITY FOR KEY ORASCAN INGREDIENT
ZILA, INC. REPORTS RECORD REVENUES
Zila Licenses OraTest Oral Cancer Detection System to Japanese Healthcare Giant, Nippon Shoji Kaisha

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters